Facebook Twitter Instagram You Tube Pinterest LinkedIn RSS Podcasts Video Library Blog
 - Northwestern Memorial Hospital - Chicago

Seema Singhal, MD

Hematology, Internal Medicine

This physician accepts new patients.Read important legal notice

You may also call Northwestern Memorial's Physician Referral Department at 1.877.926.4NMH(4664) to arrange a new patient appointment.
Office Phone: 312-695-0990
Other Languages: Hindi
Office Hours:
  • Monday:8:00 a.m. - 12:30 p.m.
  • Wednesday:8:00 a.m. - 4:00 p.m.

Clinical Interests

Multiple Myeloma, Monoclonal Antibodies, Waldenstroms, Amyloidosis, Plasma Cell Disorders, Stem Cell Transplant

Education and Training

Medical Education:

Bombay Univ.-Seth G.S. (India) 1988


Bombay Univ.-Seth G.S. (India) 1991


Hadassah Univ. Hospital (Israel) 1992

Board Certification

Internal Medicine

Locations and Directions

675 N. St. Clair
Galter 21-100
Chicago, IL 60611 312-695-0990


Dr. Singhal is currently professor of medicine and director, Multiple Myeloma Program, Division of Hematology/Oncology, at Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center at Northwestern University. Dr. Seema Singhal received her degree in medicine from Bombay University-Seth GS Medical College in India. She completed her internship at KEM Hospital in Bombay and returned to Bombay University-Seth GS Medical College to complete her residency. She then completed a bone marrow transplant fellowship at Hadassah Hospital in Jerusalem.

Dr. Singhal is a member of the American Society of Clinical Oncology, the American Society of Hematology, and the NCCN Multiple Myeloma Panel. She has edited a book on myeloma and has authored or co-authored over 590 articles, abstracts, and book chapters that have appeared in publications such as the Journal of Clinical Oncology, Blood, Bone Marrow Transplantation, and the New England Journal of Medicine. She also regularly reviews manuscripts for various journals. Dr. Singhal's current research interests include multiple myeloma with special reference to new treatment approaches including inhibition of angiogenesis, cytogenetic abnormalities, and magnetic resonance imaging; and clinical and experimental autologous and allogeneic hematopoietic stem cell transplantation. 


View the full disclosure of external professional relationships